Overview

Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of fludarabine, Velcade, and rituximab treatment regimen in patients with relapsed or refractory follicular non-Hodgkin lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Hoosier Cancer Research Network
Collaborators:
Genentech, Inc.
Millennium Pharmaceuticals, Inc.
Treatments:
Bortezomib
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine